echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > Cell Journal (IF=17) Zu Xiongbing's team at Central South University discovered a safe and effective combination therapy for the treatment of muscle-invasive bladder cancer

    Cell Journal (IF=17) Zu Xiongbing's team at Central South University discovered a safe and effective combination therapy for the treatment of muscle-invasive bladder cancer

    • Last Update: 2022-11-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    iNature

    Bladder cancer is one of the most common malignancies of the
    urinary system.
    According to the depth of invasion of local tumors, bladder cancer can be divided into non-muscle-invasive bladder cancer and muscle-invasive bladder cancer (MIBC).

    The bladder wall can be divided into four layers from the inside to the outside: mucosal layer, submucosal layer, muscular layer, and serous layer
    .
    When a tumor invades the muscular layer, serosal layer, and even the organs around the bladder, it is called muscle-invasive bladder cancer
    .

    Radical cystectomy (RC) after neoadjuvant chemotherapy (NAC) is the standard treatment
    for muscle-invasive bladder cancer (MIBC).
    Despite receiving aggressive treatment (NAC + RC), more than 40% of MIBC patients relapse or die
    within 3 years.
    In addition, NAC remains underutilized
    in most patients due to cisplatin non-eligibility or chemotherapy-related toxicity.
    Therefore, there is an urgent need to develop new treatment options
    for MIBC patients.

    On October 19, 2022, the Zu Xiongbing team of Central South University published an online publication in Cell Reports Medicine (IF=17) entitled " Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study "To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with muscle-invasive bladder cancer, and to explore predictors of efficacy, the study conducted a multicenter, real-world cohort study that demonstrated the highest rates of complete response and pathologic de-staging compared
    with neoadjuvant immunotherapy or chemotherapy.
    In conclusion, this study highlights the benefits of
    tislelizumab-based neoadjuvant combination therapy for MIBC.

    Immune checkpoint blockade (ICB), including anti-PD-1/PD-L1, has shown promising survival benefits and revolutionized the status quo
    of treatment for patients with advanced MIBC.
    The safety and efficacy of neoadjuvant ICB (NICB) in MIBC has been demonstrated
    by two prospective clinical trials.
    Similarly, the safety and efficacy of the combination of NAC and NICB in the treatment of MIBC (NAC.
    NICB)
    。 These clinical trials have initially laid the foundation
    for the clinical application of neoadjuvant therapy based on anti-PD-1/PD-L1 in MIBC.
    The role of emerging anti-PD-1/PD-L1 drugs, such as tislelizumab, in neoadjuvant therapy remains to be further studied, particularly in
    Chinese populations.
    Tislelizumab is a humanized monoclonal antibody with a higher binding affinity to the PD-1 receptor than common anti-PD-1 drugs
    .
    The second advantage of tislelizumab is its ability to minimize its binding to Fcγ receptors on macrophages, avoiding antibody-dependent phagocytosis, which is the mechanism
    of T cell clearance and potential resistance to anti-PD-1 therapy.
    Another significant advantage of tislelizumab over other anti-PD-L1/PD-1 drugs is its lower
    price.
    Current clinical trials have shown that tislelizumab significantly improves the prognosis of several advanced malignancies, including MIBC
    .
    In addition, tislelizumab combination chemotherapy has a better survival benefit and similar
    side effects compared with chemotherapy alone.
    Based on these promising results, tislelizumab has been approved
    in China.
    For the study, researchers conducted this real-world study at 15 regional medical centers to parallelize the effectiveness and safety
    of NAC, NICB, and NAC.
    By including 253 patients receiving neoadjuvant therapy from 15 tertiary hospitals (combination therapy: 98 patients, chemotherapy: 107 cases, immunotherapy: 48 cases).

    Studies have shown that neoadjuvant combination therapy achieves the highest rates of complete response and pathological de-staging compared
    with neoadjuvant immunotherapy or chemotherapy.
    Moreover, the researchers developed and validated a efficacy prediction model with clinical features of pretreatment, which can pinpoint candidates
    for neoadjuvant combination therapy.
    Preliminary studies have also found that patients who achieve pathologic complete response after neoadjuvant therapy plus maximal transurethral resection of bladder tumors may be safe, and patients who achieve pathological complete response after neoadjuvant therapy plus maximal TURBT can safely receive bladder-sparing therapy
    during short-term follow-up.
    Overview of the study (Graphed from Cell Reports Medicine) In summary, this study shows that neoadjuvant chemotherapy immunotherapy consisting of GC and tislelizumab has the highest complete response rate and pathological de-staging rate compared with neoadjuvant chemotherapy and neoadjuvant immunotherapy alone in the same real-world clinical practice setting, and neoadjuvant chemotherapy immunotherapy can be safely used in MIBC patients
    .
    In addition, the study established and validated a efficacy prediction model that could help identify candidates for neoadjuvant chemotherapy immunotherapy
    .

    Original link: #ENDcontent is 【iNature】

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.